Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
KARD Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.14B
Return on Equity (ROE)
N/A
TTM Avg
35.70%
3Y Avg
35.70%
5Y Avg
35.70%
Market Cap
$1.12B
Return on Equity (ROE)
-244.91%
TTM Avg
-17.45%
3Y Avg
-30.16%
5Y Avg
-48.76%
Market Cap
$1.13B
Return on Equity (ROE)
-50.93%
TTM Avg
-117.72%
3Y Avg
-113.46%
5Y Avg
-86.51%
Market Cap
$1.16B
Return on Equity (ROE)
2.51%
TTM Avg
3.60%
3Y Avg
0.50%
5Y Avg
-7.05%
Market Cap
$1.11B
Return on Equity (ROE)
10.23%
TTM Avg
17.11%
3Y Avg
18.25%
5Y Avg
14.55%
Market Cap
$1.17B
Return on Equity (ROE)
-17.40%
TTM Avg
-189.25%
3Y Avg
-172.42%
5Y Avg
-134.67%
Market Cap
$1.09B
Return on Equity (ROE)
22.66%
TTM Avg
22.95%
3Y Avg
21.85%
5Y Avg
17.09%
Market Cap
$1.09B
Return on Equity (ROE)
-39.54%
TTM Avg
-24.09%
3Y Avg
36.77%
5Y Avg
36.77%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kardigan, Inc. (KARD) | $1.12B | N/A | N/A | N/A | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.14B | N/A | 35.70% | 35.70% | 35.70% |
| Harrow Health, Inc. (HROW)vs › | $1.12B | -244.91% | -17.45% | -30.16% | -48.76% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.13B | -50.93% | -117.72% | -113.46% | -86.51% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 2.51% | 3.60% | 0.50% | -7.05% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.11B | 10.23% | 17.11% | 18.25% | 14.55% |
| Nektar Therapeutics (NKTR)vs › | $1.17B | -17.40% | -189.25% | -172.42% | -134.67% |
| IRadimed Corporation (IRMD)vs › | $1.09B | 22.66% | 22.95% | 21.85% | 17.09% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | -39.54% | -24.09% | 36.77% | 36.77% |
| MannKind Corporation (MNKD)vs › | $1.19B | N/A | -23.25% | -1.69% | 10.61% |
ROE
N/A
ROA
-49.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 76.67% |
